Barry Shin - 02 Jan 2026 Form 4 Insider Report for Compass Therapeutics, Inc. (CMPX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
05 Jan 2026, 16:33:59 UTC
Prior SEC filing
13 Feb 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Neil Lerner, attorney-in-fact

Key filing fact

Barry Shin filed Form 4 for Compass Therapeutics, Inc. (CMPX) on 05 Jan 2026.

Key facts

  • This page summarizes Barry Shin's Form 4 filing for Compass Therapeutics, Inc. (CMPX).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 05 Jan 2026, 16:33.

Change

  • Previous filing in this sequence was filed on 13 Feb 2025.
  • Current net transaction value: +$646,250.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001780448 Primary reporting owner

Shin Barry

Relationship
CFO
Address
C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON
Signature
/s/ Neil Lerner, attorney-in-fact
Signature date
05 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CMPX transaction

Common Stock

Award

Transaction value
$646,250
Shares
+125,000
Change %
+31%
Price
$5.17
Shares after
525,000
Date
02 Jan 2026
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CMPX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+670,000
Change %
Price
$0.000000
Shares after
670,000
Date
02 Jan 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
670,000
Exercise price
$5.17
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027.

Footnote F2

300,000 of the shares represents unvested restricted stock units ("RSU") granted on December 9, 2024. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on December 9, 2025. 125,000 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.

Footnote F3

The options vest over 48 substantially equal monthly installments starting February 2, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .